A landmark study from Jerby-Arnon, Neftel, Shore, and colleagues at the Broad Institute of Harvard and MIT, Massachusetts General Hospital, Dana-Farber Cancer Institute, and the University of Lausanne used single-cell RNA sequencing to profile 16,872 individual cells from 12 human synovial sarcoma tumors – one of the most detailed cellular portraits of this disease ever […]
North America Synovial Sarcoma Treatment Market Expected to Grow Through 2033
New industry analyses project continued growth in the North America synovial sarcoma treatment market, with a predicted compound annual growth rate (CAGR) of 4.2% from 2026 to 2033. The report reflects increasing momentum in rare cancer research, including advances in targeted therapy, immunotherapy, and precision medicine for synovial sarcoma. What’s Driving Growth in Synovial Sarcoma […]
Synovial Sarcoma Foundation Wins First Place at the 16th Annual SPAGN Conference
We are incredibly honored to share that the Synovial Sarcoma Foundation received First Place in the Advocacy in Action Award at the 16th Annual SPAGN Conference in Stockholm, Sweden. Hosted by the Sarcoma Patient Advocacy Global Network (SPAGN), this award recognizes advocacy initiatives making a meaningful impact for sarcoma patients, families, clinicians, and researchers around […]
Synovial Sarcoma Foundation Welcomes Lucia and Roberto Belluco to the Board of Directors
[Philadelphia, PA] The Synovial Sarcoma Foundation (SSF) is honored to welcome Lucia Manzinello Belluco and Roberto Belluco to its Board of Directors as the organization’s first European board members. Their appointment marks an important step in expanding the foundation’s international reach and strengthening collaboration across the global synovial sarcoma community. Lucia brings more than 20 […]
Synovial Sarcoma Treatment Market Growth Reflects Expanding Research
Recent industry analyses suggest the synovial sarcoma treatment market is expected to grow steadily, with projections estimating a compound annual growth rate (CAGR) of approximately 7.9% from 2026 to 2033. While market reports focus on financial trends and market size, they also reflect increasing investment in rare cancer research, drug development pipelines, and emerging therapies. […]
A Turning Point for Rare Cancers
What the UK’s Rare Cancers Bill Means for the Synovial Sarcoma Community For decades, patients diagnosed with rare cancers have faced a structural disadvantage. Fewer treatment options. Fewer clinical trials. Less research funding. Now a new law in the United Kingdom aims to change that. The Rare Cancers Bill, introduced by Dr Scott Arthur MP, […]
Synovial Sarcoma Foundation Hosts Second Community Webinar Highlighting Research Momentum
On February 19, 2026, the Synovial Sarcoma Foundation brought together patients, families, clinicians, and researchers from around the world for its second community webinar—an evening focused on progress, partnership, and hope. The full webinar recording is available to watch below: The webinar was moderated by Nathan Imperiale, Chairman of the Board, and featured: Highlights Foundation […]
Prasterone (DHEA) for Metastatic or Unresectable Synovial Sarcoma
Researchers have studied prasterone—also known as DHEA (dehydroepiandrosterone)—as a potential treatment option for people with synovial sarcoma that has spread (metastatic) or cannot be removed through surgery. This clinical study was designed to better understand the safety of prasterone, determine appropriate dosing, and explore whether it could help slow or control disease progression. This trial […]
Celebrating Milestones with Hope: The 100th Sign-Up for the Synovial Sarcoma Registry and Biospecimen Repository
We are thrilled to announce a significant milestone for the Synovial Sarcoma Registry and Biospecimen Repository, as we proudly welcome our 100th registrant. This achievement signifies the growing commitment to advancing research and improving treatment options for patients with synovial sarcoma. The registry serves as a pivotal resource, collecting invaluable data and biospecimens from patients […]
Synovial Sarcoma Foundation Welcomes Julie Kramer as Community Engagement & Partnerships Manager
Current Patient to Drive Relationships and Support for the Synovial Sarcoma Community [Philadelphia, PA] – 12/12/25 – The Synovial Sarcoma Foundation (SSF) is thrilled to announce the appointment of Julie Kramer as our new Community Engagement & Partnerships Manager. With a wealth of experience in advocacy and nonprofit communications, and as a survivor of synovial […]










